Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency to treat patients with relapsed and/or refractory multiple myeloma (RRMM). The authors describe the clinical presentation and management of six patients with RRMM who experienced significant cardiac toxicity associated with carfilzomib treatment.

READ FULL ARTICLE Curated publisher From Mdlinx